Amylyx Pharmaceuticals (AMLX) Rises +108.6% on Positive LUCIDITY Trial Results
Key Takeaways
- AMLX shares surged roughly +108.6% over the past 30 days, climbing from $18.50 to a recent close of $38.60, driven primarily by positive Phase 3 LUCIDITY trial results.
- The pivotal data for avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), met its primary endpoint and all secondary endpoints with a clean safety profile.
- Multiple analysts raised price targets following the readout, and the company launched—and subsequently upsized—a public offering to fund pre-commercial activities.
- Over the last quarter the stock gained roughly +200%, reflecting a broader recovery from the 2024 withdrawal of its former ALS therapy, Relyvrio.
- Near-term focus shifts to an anticipated New Drug Application (NDA) filing by the end of 2026 and a potential 2027 commercial launch.
Amylyx Pharmaceuticals (AMLX) Company Overview and Market Position
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing therapies for diseases with high unmet medical needs, spanning endocrine and neurodegenerative conditions. Its lead program is avexitide, an investigational, once-daily GLP-1 receptor antagonist in development for post-bariatric hypoglycemia, a condition characterized by dangerously low blood sugar following bariatric surgery. Avexitide holds FDA Breakthrough Therapy and Orphan Drug designations, and no FDA-approved therapy currently exists for PBH.
Beyond avexitide, the company's pipeline includes AMX0035 for Wolfram syndrome and AMX0114, an antisense oligonucleotide in Phase 1 development for amyotrophic lateral sclerosis (ALS). Amylyx previously marketed Relyvrio for ALS but voluntarily withdrew the product in 2024 after a confirmatory trial failed to meet its primary endpoint. Investors follow the stock closely because the company is transitioning from a clinical-stage developer toward its first potential commercial launch since that setback. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Amylyx Pharmaceuticals (AMLX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AMLX advanced from a closing price of $18.50 on July 21, 2026, to $38.60 as of the most recent session, a gain of approximately +108.6%. The bulk of that move occurred in a compressed window: shares jumped roughly 64% in a single session on August 18, 2026, and continued higher the following day.
The quarterly picture is even more pronounced. Three months earlier, in mid-May 2026, the stock traded near $12.74, meaning shares have risen roughly +200% over the trailing quarter. This reflects a steady upward grind through the spring and early summer—interspersed with periods of consolidation in the high-teens—before the late-stage clinical catalyst triggered an outsized re-rating. From what I see, the momentum here stands out compared to broader biotech moves.
What Drove AMLX Stock Price in the Last 30 Days
The dominant catalyst was the announcement, on August 18, 2026, of positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia. In the 78-participant, randomized, double-blind, placebo-controlled study, avexitide achieved a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared with placebo, meeting the primary endpoint agreed with the FDA. The therapy also met all secondary endpoints and demonstrated a clean safety and tolerability profile.
Because PBH has no approved treatments, the readout materially de-risked Amylyx's lead asset and reframed its path to commercialization. Analysts responded by lifting targets: H.C. Wainwright raised its target to $55 from $34, Stifel to $45 from $21, Mizuho to $42 from $30, and Robert W. Baird to $52 from $28, while Wolfe Research upgraded the stock. Separately, Guggenheim raised its target to $55 from $40, and Citi maintained a Buy rating.
Capital-raising activity also shaped trading. The company first announced a $350 million offering, then priced an upsized $500 million underwritten offering of common stock at $35.50 per share, with proceeds earmarked for pre-commercial avexitide activities, including additional manufacturing capacity, as well as research and development.
What Drove AMLX Stock Performance Over the Last Quarter
The quarterly advance reflects a broader repositioning of the company around avexitide following the 2024 withdrawal of Relyvrio. Through 2025 and into 2026, Amylyx rebuilt its clinical strategy around the PBH program, which investors increasingly viewed as an underappreciated opportunity in a large, underserved patient population. Rising expectations ahead of the LUCIDITY readout—combined with analyst target increases during the summer—pushed shares from the low-teens toward the high-teens and low-$20s before the data landed.
The company's balance sheet also underpinned the move. Amylyx has reported a cash position sufficient to fund operations into 2028, and despite posting a wider-than-expected second-quarter loss, the successful trial outcome and subsequent equity raise strengthened the financing runway toward a potential launch.
AMLX Stock Forecast Drivers: What Investors Should Watch Next
The next major milestone is Amylyx's stated plan to submit an NDA for avexitide to the FDA by the end of 2026, with a potential commercial launch in 2027 if approved. Investors will monitor the completeness and timing of that filing, as well as any regulatory feedback, label details, and manufacturing readiness.
Additional factors to watch include detailed presentations of the LUCIDITY data at upcoming medical meetings, updates on the trial's open-label extension, and progress on the company's broader pipeline, including AMX0035 and AMX0114. Valuation and dilution dynamics following the $500 million offering, ongoing cash-burn rates, and broader biotech-sector sentiment will also influence trading. As with any clinical-stage biopharmaceutical company, regulatory, commercial-execution, and competitive risks remain significant, and these considerations should be weighed alongside the positive data. I’m watching this closely as the NDA timeline approaches.
Exploring AI-Powered Trading Insights
One tool I find useful for tracking fast-moving names like AMLX is Tickeron’s Trending AI Robots page. It curates a selection of AI-powered trading bots from a broader platform offering hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured, giving traders a filtered view of the strategies currently generating the strongest signals. The bots vary widely in approach, timeframe, and performance metrics, so users can evaluate options that align with their own trading style and risk tolerance. For investors tracking clinical-stage biotechs, this can provide additional data-driven perspective alongside traditional research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AMLX sees MACD Histogram just turned negative
AMLX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 01, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 41 instances where the indicator turned negative. In of the 41 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AMLX moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMLX as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMLX broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 205 cases where AMLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.898) is normal, around the industry mean (47.012). P/E Ratio (2.686) is within average values for comparable stocks, (93.888). AMLX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.974). AMLX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.028). P/S Ratio (3.627) is also within normal values, averaging (177.092).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement